Literature DB >> 15507674

Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.

Andrew G Hadd1, Walairat Laosinchai-Wolf, Chris R Novak, Marty R Badgett, Lesley A Isgur, Marianna Goldrick, Cindy R Walkerpeach.   

Abstract

The development of simple and rapid methods for the detection of the common genetic mutations associated with cystic fibrosis (CF) requires access to positive-control samples including the 5/7/9T variants of intron 8. We used PCR and a simple multiplex bead-array assay to identify 5/7/9T control samples from 29 commercially available DNA samples. Unpurified PCR products were directly hybridized to color-coded beads containing allele-specific capture probes for 5/7/9T detection. The performance of the assay was investigated using reverse-complement oligonucleotides, individual PCR products, and multiplex PCR products for 5/7/9T detection within a complex CFTR screening assay. Samples were genotyped by grouping the relative signal intensities from each capture probe. Of 29 commercially available DNA samples analyzed, 2 5T/7T, 2 5T/9T, 9 7T/9T, 11 7T/7T, and 5 9T/9T genotypes were identified. The genotype within each sample group was confirmed by DNA sequencing. The assay was compatible with the analysis of 10 to 1000 ng of genomic DNA isolated from whole blood and allowed for the separate identification of primary CFTR mutations from reflex variants. The correct identification of positive controls demonstrated the utility of a simple bead-array assay and provided accessible samples for assay optimization and for routine quality control in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507674      PMCID: PMC1867485          DOI: 10.1016/S1525-1578(10)60531-4

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  23 in total

1.  Application of the luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: A pilot study

Authors: 
Journal:  Clin Chem       Date:  2000-09       Impact factor: 8.327

2.  Advanced multiplexed analysis with the FlowMetrix system.

Authors:  R J Fulton; R L McDade; P L Smith; L J Kienker; J R Kettman
Journal:  Clin Chem       Date:  1997-09       Impact factor: 8.327

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.

Authors:  Joshua D Groman; Timothy W Hefferon; Teresa Casals; Lluís Bassas; Xavier Estivill; Marie Des Georges; Caroline Guittard; Monika Koudova; M Daniele Fallin; Krisztina Nemeth; Gyorgy Fekete; Ludovit Kadasi; Ken Friedman; Martin Schwarz; Cristina Bombieri; Pier Franco Pignatti; Emmanuel Kanavakis; Maria Tzetis; Marianne Schwartz; Giuseppe Novelli; Maria Rosaria D'Apice; Agnieszka Sobczynska-Tomaszewska; Jerzy Bal; Manfred Stuhrmann; Milan Macek; Mireille Claustres; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

5.  A mutation in CFTR produces different phenotypes depending on chromosomal background.

Authors:  S Kiesewetter; M Macek; C Davis; S M Curristin; C S Chu; C Graham; A E Shrimpton; S M Cashman; L C Tsui; J Mickle
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

6.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

7.  Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples.

Authors:  Charles M Strom; Donghui Huang; Arlene Buller; Joy Redman; Beryl Crossley; Ben Anderson; Tom Entwistle; Weimin Sun
Journal:  Genet Med       Date:  2002 Jul-Aug       Impact factor: 8.822

8.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.

Authors:  W W Grody; G R Cutting; K W Klinger; C S Richards; M S Watson; R J Desnick
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

9.  Standards and guidelines for CFTR mutation testing.

Authors:  Carolyn Sue Richards; Linda A Bradley; Jean Amos; Bernice Allitto; Wayne W Grody; Anne Maddalena; Matthew J McGinnis; Thomas W Prior; Bradley W Popovich; Michael S Watson; Glenn E Palomaki
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

10.  Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test.

Authors:  Charles M Strom; Donghui Huang; Christina Chen; Arlene Buller; Mei Peng; Franklin Quan; Joy Redman; Weimin Sun
Journal:  Genet Med       Date:  2003 Jan-Feb       Impact factor: 8.822

View more
  3 in total

1.  Development of genomic reference materials for cystic fibrosis genetic testing.

Authors:  Victoria M Pratt; Michele Caggana; Christina Bridges; Arlene M Buller; Lisa DiAntonio; W Edward Highsmith; Leonard M Holtegaard; Kasinathan Muralidharan; Elizabeth M Rohlfs; Jack Tarleton; Lorraine Toji; Shannon D Barker; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

2.  Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P).

Authors:  Justin T Brown; Cora Lahey; Walairat Laosinchai-Wolf; Andrew G Hadd
Journal:  BMC Med Genet       Date:  2006-08-03       Impact factor: 2.103

Review 3.  Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection.

Authors:  Sherry A Dunbar
Journal:  Clin Chim Acta       Date:  2005-08-15       Impact factor: 3.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.